Correspondence to editorial on “Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma” Su Bin Lim, Hyo Jung Cho Clinical and Molecular Hepatology.2024; 30(4): 1009. CrossRef
Non-alcoholic fatty liver disease (NAFLD) may progress to cirrhotic or non-cirrhotic hepatocellular carcinoma (HCC), and is currently recognized as the fastest growing cause of HCC worldwide. Accordingly, professional society guidelines recommend HCC surveillance in patients with cirrhosis from any etiology, and some may consider it beneficial in subgroups with non-cirrhotic NAFLD at higher risk for HCC. Notably, patients with NAFLD-related HCC are more likely to have HCC diagnosed at more advanced stages and have poorer outcomes when compared to other etiologies, and suboptimal effectiveness of HCC surveillance programs is a major culprit. In this review, we summarize the current guidelines for HCC surveillance and discuss its benefits versus potential harms for NAFLD patients. We also address the unique challenges of HCC surveillance in NAFLD, including higher proportion of NAFLD-related HCC without cirrhosis, poor recognition of at-risk patients, lack of consensus regarding the value of surveillance in non-cirrhotic NAFLD, subpar effectiveness of surveillance tools related to NAFLD phenotype, and preponderant surveillance underuse among NAFLD patients. Finally, we examine the effectiveness of currently used surveillance tools (i.e., ultrasound and alpha fetoprotein) and outline future perspectives including emerging risk stratification tools, imaging surveillance strategies (e.g., abbreviated magnetic resonance imaging protocols), blood-based biomarkers (e.g., GALAD and circulating tumor DNA panels), and interventions to improve surveillance adherence.
Citations
Citations to this article as recorded by
Long-Term Survival and Recurrence in HCC vs. Non-HCC Liver Transplant Recipients: A Two-Decade Longitudinal Analysis Mahmoudreza Moein, Bridgette Nixon, Michael Leyderman, Ali Bassir, Brenden Maloney, Abolfazl Jamshidi, Matin Moallem Shahri, Amin Bahreini, Alireza Golkarieh, Reza Saidi Journal of Clinical and Experimental Hepatology.2025; 15(3): 102489. CrossRef
Editorial: PIVKA‐II Facilitates Risk Stratification for HCC Following HCV Cure Tung‐Hung Su, Wei‐Chih Liao Alimentary Pharmacology & Therapeutics.2025; 61(3): 583. CrossRef
NAFLD and NAFLD Related HCC: Emerging Treatments and Clinical Trials Tripti Khare, Karina Liu, Lindiwe Oslee Chilambe, Sharad Khare International Journal of Molecular Sciences.2025; 26(1): 306. CrossRef
A Risk Prediction Model for Hepatocellular Carcinoma in the General Population Without Traditional Risk Factors for Liver Disease Byeong Geun Song, GoEun Park, Myung Ji Goh, Wonseok Kang, Geum‐Youn Gwak, Yong‐Han Paik, Moon Seok Choi, Joon Hyeok Lee, Dong Hyun Sinn Journal of Gastroenterology and Hepatology.2025; 40(4): 979. CrossRef
Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment Soo Young Hwang, Pojsakorn Danpanichkul, Vatche Agopian, Neil Mehta, Neehar D. Parikh, Ghassan K. Abou-Alfa, Amit G. Singal, Ju Dong Yang Clinical and Molecular Hepatology.2025; 31(Suppl): S228. CrossRef
Hepatocellular carcinoma risk in ICD-coded non-cirrhotic nonalcoholic fatty liver disease refined by fatty liver index: A nationwide South Korean cohort study Chang Hun Lee, Min Gu Kang, Shinyoung Oh, In Sun Goak, Chen Shen, Ha Ram Oh, Young Ran Park, Jong Seung Kim, Ji Hyun Park Clinics and Research in Hepatology and Gastroenterology.2025; 49(6): 102612. CrossRef
High Steatosis-Associated Fibrosis Estimator scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dysfunction-associated steatotic liver disease Tung-Hung Su, Sheng-Shun Yang, Mei-Hsuan Lee, Wei-Yu Kao, Shang-Chin Huang, Fen-Fang Chen, Francis SK Poon, Lung-Wen Tsai, Yi-Ting Chen, Che Lin, Weichung Wang, W Ray Kim, Jia-Horng Kao Clinical and Molecular Hepatology.2025; 31(3): 796. CrossRef
Pathological Evolution and Internal Medicine Management of Nonalcoholic Fatty Liver Disease (NAFLD) in the Era of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Muhammad Moseeb Ali Hashim, Muhammad Aizaz Mohsin Khan, Muhammad Usama Ashraf, Saniya Mohsin, Kamran Zahoor, Javeria Niazi, Aiza Khan, Sania Muzaffar, Madiha Makhdumi, Omar Ahmed Ibad, Talha Kamran Khan, Sohaib Khalid Cureus.2025;[Epub] CrossRef
Association Between Dietary Inflammatory Index and NAFLD: A Cross‐Sectional Study of the National Health and Nutrition Examination Survey Yuan He, Yuhang Yang, Pengfei Cheng, Wei Zhang, Jinghan Jia, Dawei Ye, Jinxi Wang, Jasbir Arora (RSS) Mediators of Inflammation.2025;[Epub] CrossRef
Critical analysis of the liver cancer policies and programs in China: implications for international liver cancer control Xianwen Chen, Junnan Shi, Yan Xue, Yunfeng Lai, Menghuan Song, Carolina Oi Lam Ung, Hao Hu Global Health Research and Policy.2025;[Epub] CrossRef
A CART-based prognostic model for risk stratification of postoperative early recurrence in hepatocellular carcinoma with microvascular invasion Jie Zeng, Ri-Jin Lu, Zheng Tao, Can Zeng, Kai-Xiang Mo, Weijie Cen, Yan Lin, Rong Liang, Le-Qun Li, Guo-Bin Wu, Jia-Zhou Ye, Rong-Yun Mai Frontiers in Oncology.2025;[Epub] CrossRef
A multicenter propensity score analysis of significance of hepatic resection type for early-stage hepatocellular carcinoma Shi-Chuan Tang, Kai-Ling Zhang, Kong-Ying Lin, Yi-Dan Tang, Jun Fu, Wei-Ping Zhou, Jian-Xi Zhang, Jie Kong, Xiao-Lu He, Zheng-Hong Sun, Cong Luo, Hong-Zhi Liu, Yong-Ping Lai, Yong-Yi Zeng Hepatology International.2024; 18(2): 623. CrossRef
A risk prediction model for hepatocellular carcinoma in non‐alcoholic fatty liver disease without cirrhosis Gi‐Ae Kim, Yewan Park, Shin Ju Oh, Jooyi Jung, Seungbong Han, Hye‐Sook Chang, Sung Won Park, Tae Hyup Kim, Hye Won Park, Jaewon Choe, Jaeil Kim, Han Chu Lee Liver International.2024; 44(3): 738. CrossRef
Diagnostic performance comparisons of two commonly used multi-biomarker-based scores for detection of hepatocellular carcinoma in non-alcoholic fatty liver disease Wei Ouyang, Ming-Da Wang, Ming-Cheng Guan, Yong-Kang Diao, Li-Yang Sun, Nan-Ya Wang, Feng Shen, Hong Zhu, Tian Yang iLIVER.2024; 3(2): 100098. CrossRef
A review of MASLD-related hepatocellular carcinoma: progress in pathogenesis, early detection, and therapeutic interventions Yang Ma, Jinguo Wang, Wenping Xiao, Xiaoming Fan Frontiers in Medicine.2024;[Epub] CrossRef
Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma Jiwon Hong, Jung Woo Eun, Geum Ok Baek, Jae Youn Cheong, Seryoung Park, Soon Sun Kim, Hyo Jung Cho, Su Bin Lim Clinical and Molecular Hepatology.2024; 30(3): 360. CrossRef
Association of physical activity, including amount and maintenance, with the risk of HCC among patients with type 2 diabetes Wonkyung Han, Kyungdo Han, Seong Gyu Hwang, Sang Hoon Ahn, Mi Na Kim JHEP Reports.2024; 6(10): 101166. CrossRef
MASLD-Related HCC: A Comprehensive Review of the Trends, Pathophysiology, Tumor Microenvironment, Surveillance, and Treatment Options Yuming Shi, Erfan Taherifard, Ali Saeed, Anwaar Saeed Current Issues in Molecular Biology.2024; 46(6): 5965. CrossRef
Mapping the Hidden Terrain of Hepatocellular Carcinoma: Exploring Regional Differences in Incidence and Mortality across Two Decades by Using the Largest US Datasets Yazan Abboud, Vraj P. Shah, Michael Bebawy, Ahmed Al-Khazraji, Kaveh Hajifathalian, Paul J. Gaglio Journal of Clinical Medicine.2024; 13(17): 5256. CrossRef
Unveiling key drivers of hepatocellular carcinoma: a synergistic approach with network pharmacology, machine learning-driven ligand discovery and dynamic simulations D.K. Sabir, J.A. Bin Jumah, I. Ancy SAR and QSAR in Environmental Research.2024; 35(11): 1045. CrossRef
Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non‐alcoholic fatty liver disease Ho Soo Chun, Minjong Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Yong‐Ho Lee, Ji‐Hye Kim, Seung Up Kim Liver International.2023; 43(3): 608. CrossRef
Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how? Margaret LP Teng, Darren Jun Hao Tan, Cheng Han Ng, Daniel Q. Huang Clinical and Molecular Hepatology.2023; 29(2): 404. CrossRef
The latest global burden of liver cancer: A past and present threat Joo Hyun Oh, Dae Won Jun Clinical and Molecular Hepatology.2023; 29(2): 355. CrossRef
Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: The Next Threat after Viral Hepatitis Mohamed Salaheldin, Heba Aly, Louis Lau, Shimaa Afify, Mohamed El-Kassas Diagnostics.2023; 13(16): 2631. CrossRef
Background/Aims Surveillance for hepatocellular carcinoma (HCC) with ultrasound in high-risk populations is generally believed to improve opportunities for treatment. However, tumors are still missed due to various factors. This study explores success versus failure of HCC surveillance. Methods: This is a retrospective study of 1,125 HCC cases. Categories considered for successful detection were largest tumor ≤3.0 cm, single tumors ≤3.0 cm and ≤2.0 cm, and adherence to Milan criteria. Examined factors were age <60 years, gender, rural residence, body-mass index (BMI), hepatitis infection, smoking, diabetes, hyperlipidemia, cirrhosis, ascites, and Model for End-Stage Liver Disease <10. Results: HCC was found on surveillance in 257 patients with a mean tumor size of 3.17 cm; multiple tumors were seen in 28% of cases, bilateral tumors in 7.4%, and vascular invasion in 3.7%. Surveillance was successful in 61.5% of cases involving a largest tumor ≤3.0 cm, with BMI ≥35 negatively affecting detection (odds ratio [OR] 0.28, P=0.014) and cirrhosis positively affecting detection (OR 2.31, P=0.036). Ultrasound detected 19.1% of single tumors ≤2.0 cm with ascites improving the detection rate (OR 3.89, P=0.001). Finally, adherence to Milan criteria occurred in 75.1% of cases, revealing negative associations with diabetes (OR 0.48, P=0.044 and male gender (OR 0.49, P=0.08). Conclusions: Although surveillance is recommended for HCC, not all surveillance ultrasound are ideal. Tumor detection can depend on gender, BMI, diabetes, cirrhosis, and ascites and is achieved in 19.1–75% of cases depending on the definition of success. Closer follow-up or additional imaging might be necessary for some patient subgroups.
Citations
Citations to this article as recorded by
Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment Soo Young Hwang, Pojsakorn Danpanichkul, Vatche Agopian, Neil Mehta, Neehar D. Parikh, Ghassan K. Abou-Alfa, Amit G. Singal, Ju Dong Yang Clinical and Molecular Hepatology.2025; 31(Suppl): S228. CrossRef
Abbreviated MRI-Based Surveillance Strategies for Early Hepatocellular Carcinoma Detection Hyo Jung Park, Dong Wook Kim, Won-Mook Choi, So Yeon Kim Journal of the Korean Society of Radiology.2025; 86(3): 335. CrossRef
Proper assessment and prognostication of patients with hepatocellular carcinoma Edoardo G. Giannini Clinical Liver Disease.2024;[Epub] CrossRef
Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD Farah Abdelhameed, Chris Kite, Lukasz Lagojda, Alexander Dallaway, Kamaljit Kaur Chatha, Surinderjeet S. Chaggar, Maria Dalamaga, Eva Kassi, Ioannis Kyrou, Harpal S. Randeva Current Obesity Reports.2024; 13(3): 510. CrossRef
Detecting Early Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Using Longitudinal α-Fetoprotein Screening Jonggi Choi, Nabihah Tayob, Young-Suk Lim Clinical Gastroenterology and Hepatology.2023; 21(6): 1590. CrossRef
Development and prognosis of hepatocellular carcinoma in patients with diabetes Takuma Nakatsuka, Ryosuke Tateishi Clinical and Molecular Hepatology.2023; 29(1): 51. CrossRef
Magnetic Resonance Imaging-Based Surveillance of Hepatocellular Carcinoma: Current Status and Future Perspectives Hyo Jung Park, So Yeon Kim, Young-Suk Lim Current Hepatology Reports.2023; 22(3): 83. CrossRef
Screening of liver cancer with abbreviated MRI Maxime Ronot, Pierre Nahon, Jordi Rimola Hepatology.2023; 78(2): 670. CrossRef
From NAFLD to HCC: Advances in noninvasive diagnosis Qinchen Xu, Maoxiao Feng, Yidan Ren, Xiaoyan Liu, Huiru Gao, Zigan Li, Xin Su, Qin Wang, Yunshan Wang Biomedicine & Pharmacotherapy.2023; 165: 115028. CrossRef
Abbreviated magnetic resonance imaging vs ultrasound for surveillance of hepatocellular carcinoma in high‐risk patients Hyo Jung Park, So Yeon Kim, Amit G. Singal, So Jung Lee, Hyung Jin Won, Jae Ho Byun, Sang Hyun Choi, Takeshi Yokoo, Min‐Ju Kim, Young‐Suk Lim Liver International.2022; 42(9): 2080. CrossRef
A multi‐analyte cell‐free DNA–based blood test for early detection of hepatocellular carcinoma Nan Lin, Yongping Lin, Jianfeng Xu, Dan Liu, Diange Li, Hongyu Meng, Maxime A. Gallant, Naoto Kubota, Dhruvajyoti Roy, Jason S. Li, Emmanuel C. Gorospe, Morris Sherman, Robert G. Gish, Ghassan K. Abou‐Alfa, Mindie H. Nguyen, David J. Taggart, Richard A. V Hepatology Communications.2022; 6(7): 1753. CrossRef
Current Landscape and Future Perspectives of Abbreviated MRI for Hepatocellular Carcinoma Surveillance Hyo Jung Park, Nieun Seo, So Yeon Kim Korean Journal of Radiology.2022; 23(6): 598. CrossRef
Initiative on Superselective Conventional Transarterial Chemoembolization Results (INSPIRE) Thierry de Baere, Maxime Ronot, Jin Wook Chung, Rita Golfieri, Roman Kloeckner, Joong-Won Park, Bernhard Gebauer, Nabil Kibriya, Ganapathy Ananthakrishnan, Shiro Miyayama CardioVascular and Interventional Radiology.2022; 45(10): 1430. CrossRef
Spontaneous Regression of Hepatocellular Carcinoma From Autoinfarction and Implications on Liver Transplantation Kevin Singh ACG Case Reports Journal.2022; 9(7): e00825. CrossRef
Impact of ultrasonographic blind spots for early-stage hepatocellular carcinoma during surveillance Junghwan Lee, Su Bee Park, Soyoung Byun, Ha Il Kim, Do Young Kim PLOS ONE.2022; 17(9): e0274747. CrossRef
Current status of disparity in liver disease Tomoki Sempokuya, Josh Warner, Muaataz Azawi, Akane Nogimura, Linda L Wong World Journal of Hepatology.2022; 14(11): 1940. CrossRef
Pathogenesis to management of hepatocellular carcinoma Ben L. Da, Aiwu Ruth He, Kirti Shetty, Kelly I. Suchman, Herbert Yu, Lawrence Lau, Linda L. Wong, Atoosa Rabiee, Richard L. Amdur, James M. Crawford, Sharon S. Fox, Gregory M. Grimaldi, Priya K. Shah, Jonathan Weinstein, David Bernstein, Sanjaya K. Satapa Genes & Cancer.2022; 13: 72. CrossRef
Current status of image-based surveillance in hepatocellular carcinoma Dong Hwan Kim, Joon-Il Choi Ultrasonography.2021; 40(1): 45. CrossRef
Failure in all steps of hepatocellular carcinoma surveillance process is frequent in daily practice Melisa Dirchwolf, Sebastián Marciano, Andres E. Ruf, Amit G. Singal, Vanina D'Ercole, Paola Coisson, Alina Zerega, Federico Orozco, Ana Palazzo, Eduardo Fassio, Diego Arufe, Margarita Anders, Claudia D'Amico, Luis Gaite, Marcos Thompson, Daniela Perez, Le Annals of Hepatology.2021; 25: 100344. CrossRef
Diagnostic Performance of Simulated Abbreviated MRI for Early-Stage Hepatocellular Carcinoma Screening: A Comparison to Conventional Dynamic Contrast-Enhanced MRI Eun Sol Lim, Sung Mo Kim, Sang Soo Shin, Suk Hee Heo, Jong Eun Lee, Yong Yeon Jeong Journal of the Korean Society of Radiology.2021; 82(5): 1218. CrossRef
A Systematic Review and Narrative Synthesis of Health Economic Evaluations of Hepatocellular Carcinoma Screening Strategies Anh Le Tuan Nguyen, Hoa Thi Thu Nguyen, Kwang Chien Yee, Andrew J. Palmer, Christopher Leigh Blizzard, Barbara de Graaff Value in Health.2021; 24(5): 733. CrossRef
The APAC Score: A Novel and Highly Performant Serological Tool for Early Diagnosis of Hepatocellular Carcinoma in Patients with Liver Cirrhosis Joeri Lambrecht, Mustafa Porsch-Özçürümez, Jan Best, Fabian Jost-Brinkmann, Christoph Roderburg, Münevver Demir, Frank Tacke, Raphael Mohr Journal of Clinical Medicine.2021; 10(15): 3392. CrossRef
Reply to: “Comment on – A multi-center study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in the Republic of Korea” Beom Kyung Kim Journal of Hepatology.2020; 72(1): 198. CrossRef
Only one-third of hepatocellular carcinoma cases are diagnosed via screening or surveillance: a systematic review and meta-analysis Changqing Zhao, Feng Xing, Yee Hui Yeo, Michelle Jin, Richard Le, Michael Le, Mingjuan Jin, Linda Henry, Ramsey Cheung, Mindie H. Nguyen European Journal of Gastroenterology & Hepatology.2020; 32(3): 406. CrossRef
GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis Jan Best, Lars P. Bechmann, Jan-Peter Sowa, Svenja Sydor, Alexander Dechêne, Kristina Pflanz, Sotiria Bedreli, Clemens Schotten, Andreas Geier, Thomas Berg, Janett Fischer, Arndt Vogel, Heike Bantel, Arndt Weinmann, Jörn M. Schattenberg, Yvonne Huber, Hen Clinical Gastroenterology and Hepatology.2020; 18(3): 728. CrossRef
Tumor-associated autoantibodies in combination with alpha-fetoprotein for detection of early stage hepatocellular carcinoma Christopher Welberry, Isabel Macdonald, Jane McElveen, Celine Parsy-Kowalska, Jared Allen, Graham Healey, William Irving, Andrea Murray, Caroline Chapman, Vasilis Kosmoliaptsis PLOS ONE.2020; 15(5): e0232247. CrossRef
Exosomal microRNA‐4661‐5p–based serum panel as a potential diagnostic biomarker for early‐stage hepatocellular carcinoma Hyo Jung Cho, Geum Ok Baek, Chul Won Seo, Hye Ri Ahn, Suna Sung, Ju A Son, Soon Sun Kim, Sung Won Cho, Jeong Won Jang, Suk Woo Nam, Jae Youn Cheong, Jung Woo Eun Cancer Medicine.2020; 9(15): 5459. CrossRef
Is hepatocellular carcinoma surveillance in high-risk populations effective? Kristeen Onyirioha, Sukul Mittal, Amit G Singal Hepatic Oncology.2020;[Epub] CrossRef
Imaging Modalities for Hepatocellular Carcinoma Surveillance: Expanding Horizons beyond Ultrasound Hyo Jung Park, So Yeon Kim Journal of Liver Cancer.2020; 20(2): 99. CrossRef
Abbreviated MRI for Hepatocellular Carcinoma Screening and Surveillance Julie Y. An, Miguel A. Peña, Guilherme M. Cunha, Michael T. Booker, Bachir Taouli, Takeshi Yokoo, Claude B. Sirlin, Kathryn J. Fowler RadioGraphics.2020; 40(7): 1916. CrossRef
Validation of US Liver Imaging Reporting and Data System Version 2017 in Patients at High Risk for Hepatocellular Carcinoma Jung Hee Son, Sang Hyun Choi, So Yeon Kim, Hye Young Jang, Jae Ho Byun, Hyung Jin Won, So Jung Lee, Young Suk Lim Radiology.2019; 292(2): 390. CrossRef
Failure of hepatocellular carcinoma surveillance: inadequate echogenic window and macronodular parenchyma as potential culprits Yeun-Yoon Kim, Chansik An, Do Young Kim, Khalid Suliman Aljoqiman, Jin-Young Choi, Myeong-Jin Kim Ultrasonography.2019; 38(4): 311. CrossRef
Longitudinal assessment of alpha-fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis Mi Na Kim, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Kwang-Hyub Han, Do Young Kim Scandinavian Journal of Gastroenterology.2019; 54(10): 1283. CrossRef
Risk factors for biopsy‐proven advanced non‐alcoholic fatty liver disease in the Veterans Health Administration Y. A. Patel, E. J. Gifford, L. M. Glass, R. McNeil, M. J. Turner, B. Han, D. Provenzale, S. S. Choi, C. A. Moylan, C. M. Hunt Alimentary Pharmacology & Therapeutics.2018; 47(2): 268. CrossRef
Diffusion-weighted MRI as a screening tool for hepatocellular carcinoma in cirrhotic livers: correlation with explant data—a pilot study M. M. McNamara, J. V. Thomas, L. F. Alexander, M. D. Little, D. N. Bolus, Yufeng E. Li, D. E. Morgan Abdominal Radiology.2018; 43(10): 2686. CrossRef
Treatment for occult hepatocellular carcinoma: does it offer survival advantages over symptom-driven treatment? Kwang Min Kim, Jiyu Kim, Dong Hyun Sinn, Hye Seung Kim, Kyunga Kim, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik Scandinavian Journal of Gastroenterology.2018; 53(6): 727. CrossRef
Surveillance of hepatocellular carcinoma: is only ultrasound enough? Woo Kyoung Jeong Clinical and Molecular Hepatology.2017; 23(3): 222. CrossRef
First
Prev
